Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL.
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL. Blood Adv. 2025 Sep 09; 9(17):4405-4414.
PMID: 40554413
Usefulness and Limitations of Polymerase Chain Reaction (PCR) for the Diagnosis and Management of Toxoplasmosis Following Allogeneic Hematopoietic Cell Transplant: Single-center Experience With 31 Patients Over 16 Years.
Usefulness and Limitations of Polymerase Chain Reaction (PCR) for the Diagnosis and Management of Toxoplasmosis Following Allogeneic Hematopoietic Cell Transplant: Single-center Experience With 31 Patients Over 16 Years. Open Forum Infect Dis. 2025 Aug; 12(8):ofaf462.
PMID: 40874181
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood Adv. 2025 Jul 22; 9(14):3613-3616.
PMID: 40334078
Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment Efficacy.
Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment Efficacy. bioRxiv. 2025 May 20.
PMID: 40463198
Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma.
Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma. Nat Commun. 2025 May 06; 16(1):4205.
PMID: 40328775
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia. 2025 May; 39(5):1058-1068.
PMID: 40108332
Two-Stage CD8+ CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma.
Two-Stage CD8+ CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma. bioRxiv. 2025 Mar 15.
PMID: 40161759
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis.
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv. 2025 Mar 11; 9(5):1232-1241.
PMID: 39657136
Aggressive Management of Pulmonary Mucormycosis Necrotizing Fasciitis in a Post-Liver Transplant Patient.
Aggressive Management of Pulmonary Mucormycosis Necrotizing Fasciitis in a Post-Liver Transplant Patient. Cureus. 2025 Feb; 17(2):e78649.
PMID: 40062083
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024 Dec 10; 8(23):6139-6147.
PMID: 39093952